GlobeNewswire by notified

DBV Technologies to Participate in Upcoming Investor Conferences

Share

Montrouge, France, May 9, 2024

DBV Technologies to Participate in Upcoming Investor Conferences

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced Daniel Tassé, Chief Executive Officer, will deliver a company presentation at two investor conferences in May.

Citizens JMP Life Sciences Conference – May 13, 2024
Format:         Fireside Chat
Time:             11:00am ET
Location:       Hilton Midtown Hotel, New York, NY

H.C. Wainwright BioConnect Conference – May 20, 2024
Format:         Fireside Chat
Time:             12:00pm ET        
Location:       NASDAQ World Headquarters, New York, NY

A live webcast of each presentation will be available on the Events page on the Investors section of the Company's website www.dbv-technologies.com. A replay will also be available for 90 days after each event.

About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary technology platform, Viaskin™, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).

DBV Technologies is headquartered in Montrouge, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.

Viaskin and EPIT are trademarks of DBV Technologies.

Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com

Media Contact
Aurora Krause
DBV Technologies
aurora.krause-ext@dbv-technologies.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

EgnsINVEST Ejendomme Tyskland A/S - generalforsamlingens forløb30.5.2024 12:07:51 CEST | pressemeddelelse

30. maj Den 30. maj 2024 blev der afholdt ordinær generalforsamling i EgnsINVEST Ejendomme Tyskland A/S, CVR-nr. 30 55 77 51. Samtlige punkter på dagsordenen blev vedtaget af generalforsamlingen. Generalforsamlingen tog årsberetningen til efterretning, og årsrapporten for 2023 blev godkendt. Til bestyrelsen i selskabet blev Jan Ulsø Madsen nyvalgt og Knud Lomborg, Ane-Lene Kjølby og Thor-kild Steen Sørensen genvalgt. På det konstituerende bestyrelsesmøde efter generalforsamlingen blev Knud Lomborg genvalgt til for-mand og Ane-Lene Kjølby genvalgt som næstformand i selskabet. Generalforsamlingen genvalgte Deloitte Statsautoriseret Revisionspartnerselskab som selskabets revisor. Generalforsamlingen bemyndigede bestyrelsen til at lade selskabet tilbagekøbe egne aktier for op til i alt 10 % af aktiekapitalen frem til næste ordinære generalforsamling. Med venlig hilsen EgnsINVEST Ejendomme Tyskland A/S Kontakt vedr. ovenstående kan rettes til: Bestyrelsesformand i EgnsINVEST Ejendomme Tyskl

Ice Fish Farm – Proposed change of company name30.5.2024 11:45:07 CEST | Press release

Reykjavík, 30 May 2024 - The board of directors of Ice Fish Farm AS (the "Company") will propose that the general meeting resolves to change the company name to Kaldvik AS at the Company's annual general meeting on 20 June 2024. If approved, the Company will be trading under a new name and a new ticker immediately following the general meeting. The Company is trading its shares under the ticker "KLDVK" on Nasdaq First North Iceland already prior to the general meeting. Contacts: Róbert Róbertsson, CFO of ICE FISH FARM AS: +354 8430086 About Ice Fish Farm: Ice Fish Farm is listed on Euronext Growth Oslo. The company is the 100% owner of Fiskeldi Austfjarða ehf., the leading farming company in Iceland with its head office in Eskifjörður. The Company is fully integrated with control over all parts of the value chain. See https://www.icefishfarm.is for more information about the Company. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Secur

Rentetillæg fastsat på SDRO udstedt af Realkredit Danmark A/S30.5.2024 11:42:59 CEST | pressemeddelelse

Realkredit Danmark har fastsat tillæg på obligationer i serie 11F, 12E og 12F Realkredit Danmark offentliggør hermed tillæg til referencerenten på obligationerne bag FlexKort®, RD Cibor6® Green og RD Cibor6® som udstedes i forbindelse med refinansieringen pr. 1. juli 2024. Opdaterede Endelige vilkår offentliggøres hermed. Eventuelle spørgsmål kan rettes til Hella Gebhardt Rønnebæk, tlf. 45 13 20 68. Vedhæftede filer NewFinalTerms11FMAJ2024DKiiNewFinalTerms12FMAJ2024DKiiNewFinalTerms12EMAJ2024DKii

Publication of a Company Description30.5.2024 11:38:20 CEST | Press release

Kaldvík (Ice Fish Farm) has published a Company Description in relation to the admission to trading of the Company's Affiliated Shares on Nasdaq First North Growth Market Iceland. The Company Description, dated 24 May 2024 is attached. Nasdaq First North Growth Market Disclaimer Nasdaq First North Growth Market is a registered SME growth market, in accordance with the Directive on Markets in Financial Instruments (EU 2014/65) as implemented in the national legislation of Denmark, Finland, Iceland and Sweden, operated by an exchange within the Nasdaq group. Issuers on Nasdaq First North Growth Market are not subject to all the same rules as issuers on a regulated main market, as defined in EU legislation (as implemented in national law). Instead, they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in an issuer on Nasdaq First North Growth Market may therefore be higher than investing in an issuer on the main market.

Selskabsmeddelelse nr. 6, 2023/2430.5.2024 11:15:00 CEST | pressemeddelelse

Investeringsselskabet Luxor A/S’ bestyrelse har dags dato godkendt halvårsrapport pr. 31. marts 2024. 2. kvartal 2023/24: Basisindtjeningen er kr. 10,0 mio. (kr. 12,2 mio.). Resultat før skat er kr. 14,1 mio. (kr. 12,1 mio.). Kvartalets resultat før skat er kr. 4,1 mio. højere end basisindtjeningen, hvilket skyldes:kr. 2,5 mio. fra dagsværdiregulering af finansielle aktiver. kr. 1,6 mio. fra dagsværdiregulering af renteswaps og gæld til realkreditinstitutter. Halvåret 2023/24: Basisindtjeningen er kr. 21,9 mio. (kr. 21,7 mio.). Koncernens resultat før skat er kr. 12,9 mio. (kr. 20,3 mio.). Halvårets resultat er kr. 9,0 mio. lavere end basisindtjeningen, hvilket skyldes: kr. 5,3 mio. fra dagsværdiregulering af finansielle aktiver. kr. -14,3 mio. fra dagsværdiregulering af renteswaps og gæld til realkreditinstitutter samt omkostninger til optagelse af realkreditlån. Forventet basisindtjening 2023/24: For regnskabsåret 2023/24 forventes på indeværende tidspunkt en basisindtjening i niveau

HiddenA line styled icon from Orion Icon Library.Eye